William Waldegrave - GW Pharmaceuticals Non-Executive Independent Director
Director
The Rt. Hon. Lord William Arthur Waldegrave is NonExecutive Independent Director of the Company. He served as a Conservative Member of the British Parliament from 1979 to 1997 including sixteen years as a Government Minister, of which seven years were as a Cabinet Minister . Educated at Oxford University and Harvard, before entering Parliament he worked in the Cabinet Office in Whitehall as Political Secretary to Prime Minister Edward Heath and for GEC Ltd. Lord Waldegrave is currently Provost of Eton College, Chancellor of Reading University and a Distinguished Fellow of All Souls College, Oxford and an Honorary Fellow of Corporationrations Christi College, Oxford. From 19982008 he worked at Deutsche Kleinwort Benson and UBS. From 19982015, he served as Chairman of Biotechnology Growth Trust plc. Lord Waldegrave was appointed Chairman of Coutts in January 2014 and is Chairman of the Royal Mint Advisory Committee, former Chairman of the Rhodes Trust, a Founder Trustee of the Mandela Rhodes Foundation, and a former Chairman of the National Museum of Science and Industry. since 2017.
Tenure | 7 years |
Phone | (44) 1223 235667 |
Web | www.gwpharm.com |
GW Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (3.55) % which means that it has lost $3.55 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (7.92) %, meaning that it created substantial loss on money invested by shareholders. GW Pharmaceuticals' management efficiency ratios could be used to measure how well GW Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 43.64 M in liabilities with Debt to Equity (D/E) ratio of 0.06, which may suggest the company is not taking enough advantage from borrowing. GW Pharmaceuticals Plc has a current ratio of 4.48, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist GW Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, GW Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like GW Pharmaceuticals Plc sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for GWPH to invest in growth at high rates of return. When we think about GW Pharmaceuticals' use of debt, we should always consider it together with cash and equity.
Similar Executives
Showing other executives | DIRECTOR Age | ||
Larry Prince | Marine Products | 78 | |
Wesley Schack | Bank Of New | 70 | |
Mark Nordenberg | Bank Of New | 68 | |
Edmund Kelly | Bank Of New | 74 | |
John Hinshaw | Bank Of New | 48 | |
Catherine Rein | Bank Of New | 72 | |
Richard Kogan | Bank Of New | 73 | |
Susan Bell | Marine Products | 58 | |
Jerry Nix | Marine Products | 75 | |
john Luke | Bank Of New | 68 | |
Jennifer Morgan | Bank Of New | 48 | |
Edward Kelly | Bank Of New | 70 | |
Karin Ireton | Academy Sports OutdoorsInc | 59 | |
Nicholas Donofrio | Bank Of New | 70 | |
Harry Cynkus | Marine Products | 70 | |
Bill Dismuke | Marine Products | 82 | |
Steven Black | Bank Of New | 65 | |
Con Unerkov | Integrated Media Technology | 55 | |
Linda Graham | Marine Products | 78 | |
William Richardson | Bank Of New | 73 | |
Linda Cook | Bank Of New | 62 |
Management Performance
Return On Equity | -7.92 | |||
Return On Asset | -3.55 |
GW Pharmaceuticals Plc Leadership Team
Elected by the shareholders, the GW Pharmaceuticals' board of directors comprises two types of representatives: GW Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of GWPH. The board's role is to monitor GW Pharmaceuticals' management team and ensure that shareholders' interests are well served. GW Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, GW Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
William Waldegrave, Non-Executive Independent Director | ||
Christopher Tovey, COO, Executive Director | ||
Thomas Lynch, Non-Executive Independent Director | ||
Catherine Mackey, Non-Executive Independent Director | ||
Justin Gover, CEO, Director | ||
Geoffrey Guy, Executive Chairman of the Board | ||
James Noble, Non-Executive Deputy Chairman of the Board, Senior Independent Director | ||
Julian Gangolli, Executive Director | ||
Alicia Secor, Non-Executive Independent Director | ||
Adam George, CFO, Company Secretary, Director | ||
Cabot Brown, Non-Executive Independent Director | ||
Stephen Wright, Research & Development Director, Executive Director | ||
Darren Cline, Chief Commercial Officer, U.S. |
GWPH Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is GW Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | -7.92 | |||
Return On Asset | -3.55 | |||
Profit Margin | (11.03) % | |||
Operating Margin | (9.82) % | |||
Current Valuation | 6.42 B | |||
Shares Outstanding | 31.54 M | |||
Shares Owned By Insiders | 0.20 % | |||
Shares Owned By Institutions | 80.35 % | |||
Number Of Shares Shorted | 693.73 K | |||
Price To Earning | 126.70 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards GW Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, GW Pharmaceuticals' short interest history, or implied volatility extrapolated from GW Pharmaceuticals options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.
Other Consideration for investing in GWPH Stock
If you are still planning to invest in GW Pharmaceuticals Plc check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the GW Pharmaceuticals' history and understand the potential risks before investing.
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
Bonds Directory Find actively traded corporate debentures issued by US companies | |
Transaction History View history of all your transactions and understand their impact on performance | |
FinTech Suite Use AI to screen and filter profitable investment opportunities | |
Money Managers Screen money managers from public funds and ETFs managed around the world | |
Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios |